ATE356201T1 - Monoklonaler antikörper der faktor viii selbst in molarem überschuss nur teilweise inaktiviert und eine methode zur herstellung solch eines antikörpers - Google Patents

Monoklonaler antikörper der faktor viii selbst in molarem überschuss nur teilweise inaktiviert und eine methode zur herstellung solch eines antikörpers

Info

Publication number
ATE356201T1
ATE356201T1 AT00949329T AT00949329T ATE356201T1 AT E356201 T1 ATE356201 T1 AT E356201T1 AT 00949329 T AT00949329 T AT 00949329T AT 00949329 T AT00949329 T AT 00949329T AT E356201 T1 ATE356201 T1 AT E356201T1
Authority
AT
Austria
Prior art keywords
ligands
factor viii
factor
molar excess
complex
Prior art date
Application number
AT00949329T
Other languages
German (de)
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by D Collen Res Foundation Vzw filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of ATE356201T1 publication Critical patent/ATE356201T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00949329T 1999-07-14 2000-07-13 Monoklonaler antikörper der faktor viii selbst in molarem überschuss nur teilweise inaktiviert und eine methode zur herstellung solch eines antikörpers ATE356201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders

Publications (1)

Publication Number Publication Date
ATE356201T1 true ATE356201T1 (de) 2007-03-15

Family

ID=26315767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00949329T ATE356201T1 (de) 1999-07-14 2000-07-13 Monoklonaler antikörper der faktor viii selbst in molarem überschuss nur teilweise inaktiviert und eine methode zur herstellung solch eines antikörpers

Country Status (11)

Country Link
EP (1) EP1194528B1 (enExample)
JP (2) JP4297207B2 (enExample)
AT (1) ATE356201T1 (enExample)
AU (1) AU781638B2 (enExample)
CA (1) CA2381125C (enExample)
CY (1) CY1107638T1 (enExample)
DE (1) DE60033814T2 (enExample)
DK (1) DK1194528T3 (enExample)
ES (1) ES2283308T3 (enExample)
PT (1) PT1194528E (enExample)
WO (1) WO2001004269A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
DE60230037D1 (de) * 2001-06-12 2009-01-08 Chemo Sero Therapeut Res Inst Humanantikörper gegen blutgerinnungsfaktor viii
EP1388544A1 (en) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
JP4934796B2 (ja) * 2003-08-14 2012-05-16 トロンボジェニクス・ナムローゼ・フエンノートシャップ 可変抗体
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2616902A1 (en) * 2005-07-29 2007-02-15 Life Sciences Research Partners Vzw Human inhibitory anti-factor viii antibodies binding to the a2 domain
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
JP2019507746A (ja) 2016-03-10 2019-03-22 オクシュリオン エヌブイ 胎盤増殖因子のアンタゴナイズによる後眼部線維症の阻害
CA3062238A1 (en) * 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
WO2001004269A1 (en) 2001-01-18
AU781638B2 (en) 2005-06-02
JP2003504045A (ja) 2003-02-04
EP1194528A1 (en) 2002-04-10
CA2381125A1 (en) 2001-01-18
ES2283308T3 (es) 2007-11-01
DE60033814T2 (de) 2007-11-08
JP4297207B2 (ja) 2009-07-15
AU6273000A (en) 2001-01-30
JP4297225B2 (ja) 2009-07-15
EP1194528B1 (en) 2007-03-07
PT1194528E (pt) 2007-05-31
CY1107638T1 (el) 2013-04-18
DE60033814D1 (de) 2007-04-19
CA2381125C (en) 2013-04-23
JP2008295455A (ja) 2008-12-11
DK1194528T3 (da) 2007-07-09

Similar Documents

Publication Publication Date Title
DE60033814D1 (de) Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE434447T1 (de) Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
US20020146411A1 (en) Anticoagulant agents useful in treatment of thrombosis
CY1108566T1 (el) Ανοσολογικος ελεγχος των επιπεδων του b-αμυλοειδους in vivo
BR0011103A (pt) Composição farmacêutica, e, métodos para prevenção ou tratamento de um distúrbio caracterizado por deposição amilóide em um sujeito mamìfero, para determinar o prognóstico de um paciente que está sendo submetido a tratamento de um distúrbio amilóide e para prevenção ou tratamento de uma doença caracterizada por um depósito amilóide em um paciente
AU1922101A (en) Human fgf-21 gene and gene expression products
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
JP6705785B2 (ja) トロンビン結合性抗体分子及びその使用
EP1385864A4 (en) VASCULAR ENDOTHEL GROWTH FACTOR 2
JP2018510613A (ja) 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）抗体およびその派生使用
DE69532588D1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
Abé et al. Intramuscular keratocyst as a soft tissue counterpart of keratocystic odontogenic tumor: differential diagnosis by immunohistochemistry
DE69011531T2 (de) Von faktor vii abgeleitete peptide mit antihämostatischer wirkung.
MX2014014505A (es) Agente para prevenir y/o tratar dolor neuropatico periferico causado por farmaco contra el cancer.
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE60042487D1 (de) Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
Begbie et al. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice
Gorkun et al. Interactions mediated by the N-terminus of fibrinogen's Bβ chain
DE60042171D1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1194528

Country of ref document: EP